The Amyloid imaging to prevent Alzheimer’s disease (AMYPAD) project has reported the important advances and major achievements that have been made during the past year. The Diagnostic and Patient Management Study (DPMS) has reached the end of the clinical phase, will all 844 participants across eight European sites having completed the protocol visits and scans by the end of June 2021. The data quality check and cleaning process has been finalised. 2021 has been the most successful year to date in relation to the rate of recruitment and scanning of the Prognostic and Natural History Study (PNHS). Sites have to a large extent been able to recover from the impact of COVID-19 and three additional Parent Cohorts have joined the PNHS study, now including 10 parent cohorts of which 8 parent cohorts are actively enrolling participants into the study. In total, 1181 participants have consented into the PNHS study and 1220 scans have been performed at the end of 2021.
The collaboration within the AMYPAD consortium has been productive and efficient during the fifth year of the project. AMYPAD performed amyloid PET scans on an unprecedented scale of participants suspected to be in the early stages of Alzheimer’s disease. In parallel, technical, and operational aspects have been established and optimised. Data is being collected. 2022, the final year, will put the efforts on the data acquisition, management and analysis activities, resulting in the publication of additional results from the AMYPAD scientific work. The AMYPAD project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 115952. The Joint Undertaking receives support from the European Union’s Horizon2020 research and innovation programme and EFPIA.